BioVex Group Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 75

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $597M

BioVex Group General Information

Description

Developer of biologics for the treatment of cancer and prevention of infectious diseases. The company developed OncoVEXGM-CSF, an oncolytic vaccine that destroys cancer cells and leaves healthy and unharmed tissues and ImmunoVEXHSV2, a vaccine for genital herpes.

Contact Information

Website
www.biovex.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 34 Commerce Way
  • Woburn, MA 01801
  • United States
+1 (781)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Vertical(s)
Corporate Office
  • 34 Commerce Way
  • Woburn, MA 01801
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioVex Group Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 04-Mar-2011 $597M Completed Clinical Trials - Phase 3
11. Later Stage VC 08-Jun-2010 Completed Generating Revenue
10. Later Stage VC 11-Nov-2009 Completed Generating Revenue
9. Later Stage VC (Series F) 10-Nov-2009 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series E) 15-Nov-2007 Completed Generating Revenue
7. Mezzanine 09-Jul-2007 Completed Generating Revenue
6. IPO 20-Oct-2006 Cancelled Clinical Trials - Phase 2
5. Later Stage VC (Series D) 26-May-2005 Completed Generating Revenue
4. Later Stage VC (Series C) 03-Oct-2004 $14.5M $59M Completed Generating Revenue
3. Later Stage VC (Series B) 03-Oct-2004 $25.2M $44.5M Completed Generating Revenue
To view BioVex Group’s complete valuation and funding history, request access »

BioVex Group Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series F
Series E
Series D
Series C
Series B 18,517,457 $0.000100 $0.89 $0.89 $0.89 4.95%
Series A 95,213 $0.000100
To view BioVex Group’s complete cap table history, request access »

BioVex Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biologics for the treatment of cancer and prevention of infectious diseases. The company developed OncoVEXG
Biotechnology
Woburn, MA
75 As of 2009

Pittsburgh, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioVex Group Competitors (1)

One of BioVex Group’s competitors is Sharp Therapeutics (Biotechnology), a Formerly VC-backed company based in Pittsburgh, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sharp Therapeutics (Biotechnology) Formerly VC-backed Pittsburgh, PA
You’re viewing 1 of 1 competitors. Get the full list »

BioVex Group Patents

BioVex Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20060188480-A1 Viral vectors Active 25-Jul-2003
US-20100143309-A1 Viral vectors Active 25-Jul-2003
US-7981669-B2 Viral vectors Inactive 25-Jul-2003
US-8679830-B2 Viral vectors Inactive 25-Jul-2003
US-20030091537-A1 Anticancer agents; gene coding immunomoderator cytokine protein Active 21-Jan-2000 C12N7/00
To view BioVex Group’s complete patent history, request access »

BioVex Group Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioVex Group Former Investors (31)

Investor Name Investor Type Holding Investor Since Participating Rounds
180 Degree Capital Hedge Fund Minority
ABN AMRO Bank Investment Bank Minority
Avalon Ventures Venture Capital Minority
BMO Capital Markets Investment Bank Minority
Beringea Venture Capital Minority
You’re viewing 5 of 31 investors. Get the full list »

BioVex Group FAQs

  • When was BioVex Group founded?

    BioVex Group was founded in 1999.

  • Where is BioVex Group headquartered?

    BioVex Group is headquartered in Woburn, MA.

  • What is the size of BioVex Group?

    BioVex Group has 75 total employees.

  • What industry is BioVex Group in?

    BioVex Group’s primary industry is Biotechnology.

  • Is BioVex Group a private or public company?

    BioVex Group is a Private company.

  • What is the current valuation of BioVex Group?

    The current valuation of BioVex Group is .

  • What is BioVex Group’s current revenue?

    The current revenue for BioVex Group is .

  • How much funding has BioVex Group raised over time?

    BioVex Group has raised $233M.

  • Who are BioVex Group’s investors?

    180 Degree Capital, ABN AMRO Bank, Avalon Ventures, BMO Capital Markets, and Beringea are 5 of 31 investors who have invested in BioVex Group.

  • Who are BioVex Group’s competitors?

    Sharp Therapeutics (Biotechnology) is a competitor of BioVex Group.

  • When was BioVex Group acquired?

    BioVex Group was acquired on 04-Mar-2011.

  • Who acquired BioVex Group?

    BioVex Group was acquired by Amgen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process